Delta-Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide evaluated in preclinical literature for its regulatory influence on slow-wave sleep architecture and hypothalamic-pituitary-adrenal axis homeostasis. Designed exclusively for laboratory research use, PX1 Research provides high-purity DSIP backed by lot-specific analytical validation, including RP-HPLC purity profiles and mass spectrometry.
Delta-Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide evaluated in preclinical literature for its regulatory influence on slow-wave sleep architecture and hypothalamic-pituitary-adrenal axis homeostasis. Designed exclusively for laboratory research use, PX1 Research provides high-purity DSIP backed by lot-specific analytical validation, including RP-HPLC purity profiles and mass spectrometry.
A DSIP laboratory peptide is a high-purity, synthetically manufactured nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) reserved strictly for in vitro assays, cellular cultures, and animal models. First isolated from hemodialysate of rabbits during induced sleep, DSIP is studied in preclinical settings for its capacity to modulate delta-wave sleep induction, stress-axis reactivity, and systemic restoration during rest phases.
As a biochemical reagent, DSIP research peptide offers investigators a precise tool for examining central nervous system (CNS) signaling pathways without inducing permanent alteration of nocturnal baseline cycles. When evaluating this compound in laboratory protocols, researchers depend on rigorous purity assays to ensure reproducible experimental outcomes free from synthetic sequence contaminants or endotoxin interference. Peruse our catalog of all research peptides for additional high-purity compounds.
DSIP possesses an exact amino acid sequence of Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, yielding a molecular formula of C35H48N10O15 and a molecular weight of approximately 848.81 Da. The presence of an N-terminal tryptophan residue combined with an acidic C-terminal glutamic acid residue provides unique amphipathic properties, influencing its binding kinetics and conformational flexibility in aqueous buffers.
In physiological and laboratory conditions, the unphosphorylated nonapeptide demonstrates rapid turnover in the presence of central peptidases, though specific phosphorylated forms (such as Ser-7 phosphorylation) have been identified in preclinical models to alter biological half-life and receptor interaction dynamics. Synthetically derived DSIP used in physical biochemical investigations must exhibit precise primary structural integrity, confirmed by liquid chromatography-mass spectrometry (LC-MS) to prevent truncated peptide fragments from skewing bioassay data.
The primary focus of preclinical inquiry surrounding DSIP centers on its capacity to promote slow-wave (delta-wave) EEG activity in animal models. Unlike classic sedative compounds that operate through direct GABA-A receptor agonism, DSIP appears to function through neuromodulatory mechanisms that preserve natural sleep-wake architecture. Electrophysiological studies in rodents and non-human primates indicate that central or systemic administration of DSIP enhances delta-wave amplitude (0.5–4 Hz) during synchronized EEG phases.
In vitro and ex vivo tissue analyses suggest that DSIP interacts with central monoaminergic and peptidergic networks, modulating serotonin (5-HT) synthesis and norepinephrine turnover in cortical and hypothalamic nuclei. By influencing the activity of thalamocortical circuits responsible for generating rhythmic low-frequency oscillations, DSIP provides a focused baseline for investigating sleep architecture control without inducing traditional pharmacological tolerance or receptor desensitization.
Beyond central EEG modulation, preclinical research demonstrates that DSIP exerts a pronounced regulatory influence over the hypothalamic-pituitary-adrenal (HPA) stress axis. In animal models subjected to acute or chronic physiological stress protocols, DSIP administration has been observed to normalize elevated plasma corticosterone and adrenocorticotropic hormone (ACTH) levels, stabilizing baseline endocrine output.
This stress-dampening effect is thought to occur through central peptidergic modulation within the paraventricular nucleus (PVN) of the hypothalamus. Preclinical trials demonstrate that DSIP inhibits stress-induced hypersecretion of corticotropin-releasing hormone (CRH), thereby mitigating downstream metabolic and immunological cascades associated with chronic stress exposure. Investigators frequently utilize DSIP to study cross-talk between circadian rhythm regulation and neuroendocrine stress resilience in specialized rodent paradigms.
When designing protocols to investigate neuroendocrine restoration, sleep architecture, or central stress responses, researchers frequently compare DSIP to other signaling peptides within related biochemical classes. While DSIP targets slow-wave sleep initiation and HPA axis recalibration, peptides like epitalon laboratory peptide focus primarily on telomerase expression and pineal melatonin synthesis, offering a distinct pathway for circadian bio-clock restoration.
Similarly, neuropeptides such as selank peptide overview and semax research compound target neurotrophic factor expression (BDNF/NGF) and enkephalin breakdown inhibition to modulate anxiety and cognitive performance, rather than directly inducing delta-wave synchronization. Comparing these compounds highlights DSIP's unique status as a specific electrophysiological sleep modulator rather than a broad neurotrophic or telomeric agent. Further research models explore synergies between neuropeptides and growth hormone secretagogues like ghrp-6 research peptide or cjc-1295 research when analyzing nocturnal endocrine secretion patterns.
Preclinical data suggest that DSIP-mediated delta-wave enhancement correlates with systemic recovery metrics at the cellular level. In animal research models exposed to physical or environmental stressors, researchers have observed reductions in oxidative stress markers—such as malondialdehyde (MDA)—and increases in endogenous antioxidant enzyme activity (superoxide dismutase, catalase) following DSIP application.
Additionally, ex vivo assays examining mitochondrial membrane potential in neural and peripheral tissues show that DSIP helps maintain cellular energy balance under hypoxia or metabolic stress. By limiting lipid peroxidation and mitigating stress-induced cellular damage, DSIP serves as a vital tool in preclinical research focused on tissue preservation, nocturnal metabolic efficiency, and neuroprotective recovery mechanisms. Detailed literature can be reviewed in our peptides research library.
Proper preparation of DSIP is necessary to maintain peptide structural integrity and prevent aggregation or cleavage prior to experimental assays. DSIP is supplied as a lyophilized white powder under vacuum or inert gas flushing. It exhibits high solubility in sterile, deionized water or standard phosphate-buffered saline (PBS, pH 7.4).
To reconstitute for laboratory use, allow the vial to reach room temperature before adding the desired volume of sterile diluent (such as bacteriostatic water or sterile standard saline). Gently swirl or invert the vial until complete dissolution occurs; mechanical vortexing or aggressive shaking must be avoided to prevent surface-denaturation of the nonapeptide chain. Reconstituted stock solutions should be aliquot-divided into sterile microcentrifuge tubes to prevent repeated freeze-thaw cycles during longitudinal in vitro or animal studies.
Lyophilized DSIP maintains long-term stability when stored at -20°C or -80°C in a desiccated environment protected from light exposure. Under these optimal conditions, the dry peptide retains chemical stability and potency for up to 24 months. Storage at ambient room temperatures (20°C–25°C) should be limited to short-term transport or immediate assay setup.
Once reconstituted into aqueous solution, DSIP is subject to enzymatic cleavage and spontaneous chemical degradation over time. Reconstituted liquid aliquots should be refrigerated at 2°C–8°C for short-term use (up to 7–14 days depending on diluent sterility) or stored at -20°C for extended experimental timeframes. Exposure to elevated temperatures, extreme pH environments, or direct ultraviolet light accelerates peptide bond hydrolysis, specifically targeting the tryptophan-alanine peptide bond.
Because preclinical research demands consistent, reproducible data, verifying the purity of laboratory DSIP is paramount. Imparting chemical integrity requires two primary analytical methodologies: Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to establish chemical purity percentage, and Electrospray Ionization Mass Spectrometry (ESI-MS) to verify precise molecular mass (848.81 Da).
PX1 Research enforces strict quality control standards for every production lot. Each batch of DSIP undergoes independent testing at an ISO 17025-accredited laboratory within the United States. Certificates of Analysis (COAs) accompany every lot, confirming >98% purity, exact mass verification, and stringent endotoxin testing (<0.01 EU/mg via LAL assay) to ensure compliance with advanced cellular and animal research protocols.
Selecting a reliable USA-based supplier is critical for maintaining research integrity and avoiding lot-to-lot variability. Impurities, heavy metals, or residual synthesis reagents can confound biological data, alter binding affinities, or induce off-target toxicities in delicate in vitro cell models or animal subjects.
PX1 Research operates dedicated GMP-compliant synthesis facilities, offering fully traceable, high-purity compounds directly to academic institutions, biotechnology firms, and independent research laboratories. Institutional buyers and facility directors seeking bulk supply or custom formulations can explore tailored options through our bulk lab supply accounts program.
What is the primary research application of DSIP laboratory peptide?
DSIP (Delta-Sleep-Inducing Peptide) is primarily utilized in preclinical research to study slow-wave (delta-wave) sleep induction, neuroendocrine balance, and hypothalamic-pituitary-adrenal (HPA) axis stress responses in animal and cellular models.
How is DSIP purity validated at PX1 Research?
Every lot of DSIP undergoes rigorous third-party analytical testing at an ISO 17025-accredited laboratory, using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity quantification (>98%) and Mass Spectrometry (MS) for exact molecular weight confirmation.
What is the molecular weight and sequence of DSIP?
DSIP is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu and a theoretical molecular weight of 848.81 Da.
What are the recommended storage conditions for lyophilized DSIP?
Lyophilized DSIP should be stored in a freezer at -20°C or -80°C in a desiccated environment protected from light. Under these conditions, the peptide remains stable for up to 24 months.
How should reconstituted DSIP solutions be stored for lab experiments?
After reconstitution in sterile aqueous diluents, liquid DSIP aliquots should be stored at 2°C–8°C for short-term use (up to 7–14 days) or frozen at -20°C to prevent degradation. Repeated freeze-thaw cycles must be avoided.
Are PX1 Research peptides endotoxin tested?
Yes. Every batch of DSIP undergoes Limulus Amebocyte Lysate (LAL) testing to ensure endotoxin levels remain strictly below <0.01 EU/mg, preventing unwanted immunological interference in biological assays.
Can DSIP be reconstituted in standard phosphate-buffered saline (PBS)?
Yes. DSIP exhibits high solubility in sterile, pH-neutral aqueous solvents including standard PBS (pH 7.4), sterile water, or normal saline for laboratory bioassays.
Is DSIP approved for human consumption or medical therapy?
No. DSIP supplied by PX1 Research is strictly designated for laboratory research use only (in vitro and preclinical animal models) and is not intended for human or veterinary medical, therapeutic, or diagnostic use.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.